---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-009807"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:33:34.050130+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete

## Summary
- Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.
- Cash and marketable securities of $105.8M as of Dec 31, 2023; expected runway into first half of 2026.
- OV888 (GV101) Phase 1 multiple-ascending dose study progressing; no serious adverse events; higher dose cohort added.
- Net loss of $52.3M for full year 2023 compared to $54.2M in 2022; basic net loss per share $0.74.
- Ovid retains 87% interest in soticlestat milestones and royalties; potential payments up to $660M plus low double-digit royalties.

## SEC filing metadata
- accession: 0001628280-24-009807
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/0001628280-24-009807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/ovid-20240308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-009807
- JSON: https://secwatch.observer/filing/0001628280-24-009807.json
- Plain text: https://secwatch.observer/filing/0001628280-24-009807.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Fourth Quarter and Full Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/0001628280-24-009807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.